Subtopic Deep Dive

TGF-β in Epithelial-Mesenchymal Transition
Research Guide

What is TGF-β in Epithelial-Mesenchymal Transition?

TGF-β induces epithelial-mesenchymal transition (EMT) in carcinoma cells through Smad-dependent activation of transcription factors like Snail and ZEB, driving tumor invasion and metastasis.

TGF-β signaling triggers EMT by repressing E-cadherin and inducing mesenchymal markers via Smad3/4 complexes (Xu et al., 2009, 2737 citations). This process integrates with pathways like NF-κB and Notch for partial EMT states (Huber et al., 2004, 835 citations; Zavadil et al., 2004, 737 citations). Over 10 key papers from 2000-2022 detail mechanisms in cancer progression.

Curated Papers

Key Challenges

Why It Matters

EMT induced by TGF-β enables carcinoma invasion, metastasis, and chemotherapy resistance, as shown in breast cancer models where NF-κB cooperates with TGF-β (Huber et al., 2004). Targeting TGF-β signaling inhibits fibrosis and tumor spread, with therapeutic potential validated in renal models (Sato et al., 2003) and cancer studies (Peng et al., 2022). These insights guide anti-metastatic drug development, including Smad inhibitors (Massagué et al., 2000; Yang et al., 2019).

Key Research Challenges

Partial EMT Heterogeneity

TGF-β induces hybrid epithelial/mesenchymal states rather than full transitions, complicating metastasis models (Xu et al., 2009). Single-cell variability challenges uniform targeting (Yang et al., 2019). Over 5 papers highlight context-dependent outcomes.

Signaling Crosstalk Complexity

TGF-β/Smad integrates with NF-κB and Notch, amplifying EMT in breast cancer (Huber et al., 2004; Zavadil et al., 2004). Dissecting pathway dominance remains difficult (Heldin et al., 2009). Therapeutic interference risks off-target effects (Peng et al., 2022).

EMT Reversibility Mechanisms

TGF-β-driven EMT shows partial reversibility in metastasis, linked to Snail1-Smad complexes (Vincent et al., 2009). Factors controlling mesenchymal-to-epithelial transition are underexplored (Zavadil and Böttinger, 2005). Fibrosis models reveal Smad3 dependence (Sato et al., 2003).

Essential Papers

TGF-β-induced epithelial to mesenchymal transition

Jian Xu, Samy Lamouille, Rik Derynck · 2009 · Cell Research · 2.7K citations

TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders

Joan Massagué, Stacy W. Blain, Roger S. Lo · 2000 · Cell · 2.4K citations

TGF-β and epithelial-to-mesenchymal transitions

Jiří Zavadil, Erwin P. Böttinger · 2005 · Oncogene · 1.6K citations

TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

Hao Yang, D.A. Baker, Peter ten Dijke · 2019 · International Journal of Molecular Sciences · 1.1K citations

Transforming growth factor β (TGF-β) is a secreted cytokine that regulates cell proliferation, migration, and the differentiation of a plethora of different cell types. Consistent with these findin...

Targeting TGF-β signal transduction for fibrosis and cancer therapy

Dandan Peng, Minyang Fu, Manni Wang et al. · 2022 · Molecular Cancer · 891 citations

NF-κB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression

Margit A. Huber, Ninel Azoitei, Bernd Baumann et al. · 2004 · Journal of Clinical Investigation · 835 citations

The transcription factor NF-κB is activated in a range of human cancers and is thought to promote tumorigenesis, mainly due to its ability to protect transformed cells from apoptosis. To investigat...

Integration of TGF‐β/Smad and Jagged1/Notch signalling in epithelial‐to‐mesenchymal transition

Jiří Zavadil, Lukáš C̆ermák, Noemí Soto-Nieves et al. · 2004 · The EMBO Journal · 737 citations

Reading Guide

Foundational Papers

Start with Xu et al. (2009, 2737 citations) for core TGF-β EMT mechanisms; Massagué et al. (2000, 2365 citations) for signaling overview; Zavadil and Böttinger (2005, 1573 citations) for transitions in cancer.

Recent Advances

Yang et al. (2019, 1074 citations) on metastasis; Peng et al. (2022, 891 citations) on therapies; Vincent et al. (2009, 629 citations) on Snail1-Smad complexes.

Core Methods

TGF-β treatment in epithelial cells; Smad phosphorylation assays; ChIP for transcription factors; xenograft models for invasion (Xu et al., 2009; Huber et al., 2004).

How PapersFlow Helps You Research TGF-β in Epithelial-Mesenchymal Transition

Discover & Search

Research Agent uses citationGraph on Xu et al. (2009) to map 2737-citing papers, revealing EMT clusters; exaSearch queries 'TGF-β Snail ZEB carcinoma' for 250M+ OpenAlex papers; findSimilarPapers expands from Massagué et al. (2000) to related signaling reviews.

Analyze & Verify

Analysis Agent applies readPaperContent to extract Smad3/4 mechanisms from Vincent et al. (2009); verifyResponse with CoVe cross-checks NF-κB/EMT claims against Huber et al. (2004); runPythonAnalysis plots citation trends and GRADE scores evidence strength for pathway integrations.

Synthesize & Write

Synthesis Agent detects gaps in partial EMT reversibility from Xu et al. (2009) and Yang et al. (2019); Writing Agent uses latexSyncCitations for 10-paper bibliographies, latexCompile for figures, and exportMermaid to diagram TGF-β/Smad/Notch crosstalk.

Use Cases

"Analyze Snail1-Smad3 complex data from Vincent 2009 with stats on EMT markers"

Research Agent → searchPapers 'SNAIL1 SMAD3 TGF-β' → Analysis Agent → readPaperContent + runPythonAnalysis (pandas quantify E-cadherin repression) → matplotlib plots of marker expression.

"Draft LaTeX review on TGF-β EMT in breast cancer with citations"

Research Agent → citationGraph 'Huber 2004 NF-κB EMT' → Synthesis → gap detection → Writing Agent → latexEditText + latexSyncCitations (10 papers) + latexCompile → PDF with EMT pathway figure.

"Find code for TGF-β signaling simulations in EMT models"

Research Agent → searchPapers 'TGF-β EMT simulation' → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runnable Python for Smad dynamics.

Automated Workflows

Deep Research workflow scans 50+ TGF-β EMT papers via searchPapers → citationGraph → structured report with GRADE-verified mechanisms from Xu et al. (2009). DeepScan applies 7-step CoVe to validate crosstalk in Huber et al. (2004) and Zavadil et al. (2004). Theorizer generates hypotheses on partial EMT targeting from Peng et al. (2022).

Try Doxa for TGF-β in Epithelial-Mesenchymal Transition Research

Frequently Asked Questions

What defines TGF-β-induced EMT?

TGF-β activates Smad3/4 to upregulate Snail and ZEB, repressing E-cadherin for mesenchymal shift (Xu et al., 2009; Vincent et al., 2009).

What are main methods studying TGF-β EMT?

Cell models use TGF-β treatment with qPCR/Western blots for markers; mouse xenografts assess metastasis (Huber et al., 2004); ChIP assays map Smad-Snail binding (Vincent et al., 2009).

What are key papers on TGF-β EMT?

Xu et al. (2009, 2737 citations) reviews mechanisms; Massagué et al. (2000, 2365 citations) covers cancer roles; Yang et al. (2019, 1074 citations) details metastasis.

What open problems exist in TGF-β EMT?

Hybrid EMT states and reversibility lack predictors (Xu et al., 2009); pathway crosstalk inhibitors cause resistance (Peng et al., 2022); single-cell dynamics need mapping.